![Comparing antibody expression and staining intensity between BD FACSCANTO II and Sysmex XF-1600 in Follicular Lymphoma progressing to B-Lymphoblastic leukaemia/lymphoma](/fileadmin/_processed_/b/e/csm_Poster-_Follicular_lymphoma_progression__Woodhead_Stevens_RHH_at_ESCCA_2021__a0682bbeca.png)
Follicular lymphoma (FL) is the most common form of indolent lymphoma in the western world, accounting for approximately 25% of malignant lymphomas (Ciabanu et al 2013). Disease progression of FL is often unpredictable with 25% - 30% of FL cases progressing; most commonly to diffuse large B cell lymphoma, Hodgkin lymphoma, Burkitt lymphoma and rarely B-lymphoblastic leukaemia/lymphoma (B-ALL) (Swerdlowetal, 2017).
File type:
pdf
File size:
671 KB
Release:
10-08-22